Page last updated: 2024-08-26

bosentan anhydrous and Down Syndrome

bosentan anhydrous has been researched along with Down Syndrome in 13 studies

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (30.77)29.6817
2010's9 (69.23)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Crepaz, R; De Santis, S; Montanaro, D; Romeo, C1
Chen, Y; Feng, Y; He, J; Ren, Y1
He, F; Ren, R; Xiao, X1
Yao, A1
Berger, RM; Bouma, BJ; Duffels, MG; Hoendermis, ES; Mulder, BJ; van Dijk, AP; van Loon, RL; Vis, JC1
Berger, RM; Bouma, BJ; Bresser, P; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Nieuwkerk, PT; van Dijk, AP; van Loon, RL; Vis, JC1
Doherty, DR; Eipe, N; Lai, L1
Franks, C; Hall, K; Kermeen, FD; McNeil, K; O'Brien, K; Radford, D; Seale, H1
Berger, RM; Bouma, BJ; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Mulder, P; van Dijk, AP; Vis, JC1
Argiento, P; Bossone, E; CalabrĂ², R; Correra, A; D'Alto, M; D'Andrea, A; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Scognamiglio, G; Vizza, CD1
Clarke, B; Griffiths, L; Mahadevan, VS; Monfredi, O1
D'Alto, M; Mahadevan, VS1
Christopoulos, A; Kourouklis, S; Kyriakides, ZS; Liagkas, K; Paradellis, G1

Reviews

1 review(s) available for bosentan anhydrous and Down Syndrome

ArticleYear
Pulmonary arterial hypertension associated with congenital heart disease.
    European respiratory review : an official journal of the European Respiratory Society, 2012, Dec-01, Volume: 21, Issue:126

    Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Comorbidity; Down Syndrome; Eisenmenger Complex; Endothelium, Vascular; Epoprostenol; Health Behavior; Heart Defects, Congenital; Heart Transplantation; Humans; Hypertension, Pulmonary; Lung Transplantation; Oxygen Inhalation Therapy; Phosphodiesterase 5 Inhibitors; Piperazines; Practice Guidelines as Topic; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thrombosis

2012

Trials

1 trial(s) available for bosentan anhydrous and Down Syndrome

ArticleYear
Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
    International journal of cardiology, 2013, Apr-15, Volume: 164, Issue:3

    Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome; Young Adult

2013

Other Studies

11 other study(ies) available for bosentan anhydrous and Down Syndrome

ArticleYear
Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.
    BMC cardiovascular disorders, 2013, Sep-18, Volume: 13

    Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Eisenmenger Complex; Exercise Test; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Male; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Young Adult

2013
Bosentan treatment for pulmonary arterial hypertension due to patent ductus arteriosus and Down's syndrome in an infant.
    International journal of cardiology, 2014, Oct-20, Volume: 176, Issue:3

    Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Infant; Male; Sulfonamides; Treatment Outcome

2014
Bosentan treatment for pulmonary arterial hypertension due to complete atrioventricular septal defect in an infant with Down's syndrome.
    International journal of cardiology, 2014, Dec-20, Volume: 177, Issue:3

    Topics: Antihypertensive Agents; Bosentan; Down Syndrome; Heart Septal Defects; Humans; Hypertension, Pulmonary; Infant; Male; Mitral Valve Insufficiency; Sulfonamides; Treatment Outcome; Ultrasonography

2014
Medical treatment for an adult patient with eisenmenger syndrome. A case report.
    International heart journal, 2015, Volume: 56 Suppl

    Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Eisenmenger Complex; Endothelin Receptor Antagonists; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Sulfonamides

2015
Down patients with Eisenmenger syndrome: is bosentan treatment an option?
    International journal of cardiology, 2009, May-29, Volume: 134, Issue:3

    Topics: Adult; Bosentan; Down Syndrome; Eisenmenger Complex; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sulfonamides; Treatment Outcome; Young Adult

2009
Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
    The American journal of cardiology, 2009, May-01, Volume: 103, Issue:9

    Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Probability; Quality of Life; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Sulfonamides; Treatment Outcome; Young Adult

2009
Severe pulmonary hypertension and adenotonsillectomy in a child with Trisomy-21 and obstructive sleep apnea.
    Paediatric anaesthesia, 2009, Volume: 19, Issue:5

    Topics: Adenoidectomy; Anesthetics, Intravenous; Anticoagulants; Antihypertensive Agents; Bosentan; Child; Down Syndrome; Elective Surgical Procedures; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Intubation, Intratracheal; Piperazines; Piperidines; Propofol; Purines; Remifentanil; Severity of Illness Index; Sildenafil Citrate; Sleep Apnea, Obstructive; Sulfonamides; Sulfones; Tonsillectomy; Treatment Outcome; Vasodilator Agents; Warfarin

2009
Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Heart, lung & circulation, 2010, Volume: 19, Issue:10

    Topics: Adult; Antihypertensive Agents; Bosentan; Confidence Intervals; Down Syndrome; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Heart Defects, Congenital; Humans; Hypertension; Male; Prospective Studies; Pulmonary Artery; Sulfonamides; Time Factors; Walking

2010
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.
    International journal of cardiology, 2013, Mar-20, Volume: 164, Issue:1

    Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Survival Rate; Time Factors

2013
Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
    The American journal of cardiology, 2011, Nov-15, Volume: 108, Issue:10

    Topics: Adult; Aged; Alanine Transaminase; Antihypertensive Agents; Aspartate Aminotransferases; Bosentan; Down Syndrome; Exercise Tolerance; Female; Heart Defects, Congenital; Hemoglobins; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen; Retrospective Studies; Sex Factors; Sulfonamides

2011
Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension.
    European journal of clinical investigation, 2006, Volume: 36 Suppl 3

    Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Down Syndrome; Echocardiography, Doppler; Eisenmenger Complex; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Sulfonamides; Treatment Outcome

2006